Professor Borislava (Boby) Mihaylova, DPhilProfessor of Health Economics & Lead of Health Economics and Policy Research Unit Email: b.mihaylova@qmul.ac.ukTelephone: Tel: +44 (0)20 7882 3863ProfileTeachingResearchPublicationsSupervisionProfileI am a health economist with an academic background in Computer Science and Finance (Technical University-Sofia, Bulgaria), Health Economics (University of York, UK) and a DPhil in Public Health and Health Economics (University of Oxford, UK). Early in my career I became involved in the development of the National Health Insurance system in Bulgaria and worked on the design and implementation of case-mix payment methods of hospital care. My MSc study in Health Economics at the University of York deepened my interest in health economics methods to assess value of health policies, services, and treatments. A NHS Training Fellowship enabled me to undertake DPhil at the University of Oxford studying the cost-effectiveness of statins in people at different risks of cardiovascular disease using large clinical studies. Thereafter, I investigated the value of statins, ezetimibe, blood pressure treatment, and niacin across patients by sex, age and cardiovascular risk, contributing to the widening of recommendations for statin and blood pressure treatment to people at lower cardiovascular risk, and discontinuing use of niacin due to safety concerns. At the Wolfson Institute of Population Health, QMUL, I lead research on impact of diseases and treatments on morbidity, mortality, health-related quality of life and healthcare/other resources and costs; cost-effectiveness of prevention and treatment strategies; and development of evaluative frameworks and disease models to assess net effects of policies and treatments. My team develops applied and methodological research across high burden disease areas and public health problems aiming to contribute robust evidence that reliably informs national and international health policy. I teach graduate and undergraduate students and supervise PhD students. I am a co-director of the Wellcome Trust PhD Programme in Science “Health data in practice: human-centred science” and co-lead the MSc module “Health Economic Analyses”.TeachingHealth Economic Analyses Module, MSc Global Health Effective and Efficient Evaluation Module, MRes in Health Data in PracticeResearchResearch Interests:My research expertise lies across the areas of health economics and health technology assessment and includes primary and evidence synthesis research. I have a particular interest in developing evaluative frameworks using individual people data sources to inform more targeted policy decisions. PublicationsPlease click through to see a complete list of Borislava's publications Outstanding Publications Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet, 2012; 380(9841):581-590. Heart Protection Study Collaborative Group. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ 2006;333:1145 Schlackow I, Simons C, Oke J, Feakins B, O'Callaghan CA, Hobbs FDR, Lasserson D, Stevens RJ, Perera R, Mihaylova B. Long-term health outcomes of people with reduced kidney function in the UK: A modelling study using population health data. PLoS Med. 2020 Dec 16;17(12):e1003478. Schlackow I, ..., Borislava Mihaylova, ..., C. Tomson, Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease. Kidney International, 2019;96(1):170-179. Kent S, ..., Borislava Mihaylova, ...., Sudlow C. Hospital costs in relation to body mass index in 1.1 million women in England: a prospective cohort study. Lancet Public Health, 2017;2(5): e214-e222. Edwards MR, Forbes G, Walker N et al. (2023). Fluid Optimisation in Emergency Laparotomy (FLO-ELA) Trial: study protocol for a multi-centre randomised trial of cardiac output-guided fluid therapy compared to usual care in patients undergoing major emergency gastrointestinal surgery. nameOfConference DOI: 10.1186/s13063-023-07275-3 QMRO: qmroHref Scales J, Chavda J, Ikeda E et al. (2023). Device-Measured Change in Physical Activity in Primary School Children During the UK COVID-19 Pandemic Lockdown: A Longitudinal Study.. nameOfConference DOI: 10.1123/jpah.2022-0434 QMRO: qmroHref Zhou J, Wu R, Williams C et al. (2023). Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK. nameOfConference DOI: 10.1007/s40273-022-01219-6 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/84967 Thalmann I, Preiss D, Schlackow I et al. (2023). Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009-2017. nameOfConference DOI: 10.1136/heartjnl-2022-321452 QMRO: qmroHref Roukas C, Miller L, Hamborg T et al. (2023). DOP23 Decrements in quality of life associated with symptoms of Inflammatory Bowel Disease: results from the UK IBD-BOOST survey. nameOfConference DOI: 10.1093/ecco-jcc/jjac190.0063 QMRO: qmroHref Hart A, Miller L, Hamborg T et al. (2023). DOP59 What is the relationship between fatigue, pain and urgency in people with inflammatory bowel disease? Results of the IBD-BOOST survey in 8486 participants. nameOfConference DOI: 10.1093/ecco-jcc/jjac190.0099 QMRO: qmroHref Willliam C, Lui NMJ, Bowman L et al. (2022). CHALLENGES IN EXTRAPOLATION WHEN THERE ARE MULTIPLE HEALTH OUTCOMES. nameOfConference DOI: doi QMRO: qmroHref Williams C, Lui N, Bowman L et al. (2022). MSR45 Challenges in Extrapolation When There Are Multiple Health Outcomes. nameOfConference DOI: 10.1016/j.jval.2022.09.1776 QMRO: qmroHref Jumbe S, Madurasinghe VW, James WY et al. (2022). STOP— a training intervention to optimise treatment for smoking cessation in community pharmacies: cluster randomised controlled trial. nameOfConference DOI: 10.1186/s12916-022-02412-2 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/79520 Keng MJ, Leal J, Bowman L et al. (2022). Hospital costs associated with adverse events in people with diabetes in the UK. nameOfConference DOI: 10.1111/dom.14796 QMRO: qmroHref Thalmann I, Preiss D, Schlackow I et al. (2022). Antiplatelet therapy use for the secondary prevention of cardiovascular disease in 2009–2017: a population-wide retrospective cohort study of Scotland. nameOfConference DOI: 10.1093/eurheartj/ehac544.2328 QMRO: qmroHref Wu R, Williams C, Zhou J et al. (2022). Benefit accrual with cardiovascular disease prevention and effects of discontinuation: a modelling study. nameOfConference DOI: 10.1093/eurheartj/ehac544.2850 QMRO: qmroHref Mihaylova B, Wu R, Williams C et al. (2022). Cost-effectiveness of statin therapy in categories of patients in the UK. nameOfConference DOI: 10.1093/eurheartj/ehac544.2841 QMRO: qmroHref Zhou J, Wu R, Williams C et al. (2022). Impact of cardiovascular events on primary and hospital care costs: findings from UK Biobank study. nameOfConference DOI: 10.1093/eurheartj/ehac544.2852 QMRO: qmroHref Cholesterol Treatment Trialists' Collaboration (2022). Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.. nameOfConference DOI: 10.1016/S0140-6736(22)01545-8 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/82610 Schmierer K, Baker D, Nawaz T et al. (2022). 153 ChariotMS – cladribine to halt deterioration in people with advanced multiple sclerosis (pwAMS). nameOfConference DOI: 10.1136/jnnp-2022-abn2.197 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/80209 Roukas C, Syred J, Gordeev VS et al. (2022). Development and test-retest reliability of a new, self-report questionnaire assessing healthcare use and personal costs in people with inflammatory bowel disease: The Inflammatory Bowel Disease Resource Use Questionnaire (IBD-RUQ). nameOfConference DOI: 10.1136/flgastro-2022-102182 QMRO: qmroHref Castellani J, Kimbute O, Makasi C et al. (2022). Daily Life and Challenges Faced By Households With Permanent Childhood Developmental Disability in Rural Tanzania – A Qualitative Study. nameOfConference DOI: 10.1007/s10882-021-09809-6 QMRO: qmroHref Sammons E, Hopewell JC, Chen F et al. (2022). Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. nameOfConference DOI: 10.1093/eurheartj/ehab863 QMRO: qmroHref Keng MJ, Armitage J, Bowman L et al. (2022). IDF21-0188 Impact of adverse events on hospital costs and health-related quality of life in people with diabetes. nameOfConference DOI: 10.1016/j.diabres.2022.109257 QMRO: qmroHref Keng MJ, Leal J, Bowman L et al. (2022). Decrements in health-related quality of life associated with adverse events in people with diabetes. nameOfConference DOI: 10.1111/dom.14610 QMRO: qmroHref Keng MJ, Leal J, Mafham M et al. (2022). Performance of the UK Prospective Diabetes Study Outcomes Model 2 in a Contemporary UK Type 2 Diabetes Trial Cohort. nameOfConference DOI: 10.1016/j.jval.2021.09.005 QMRO: qmroHref Levy M, Chen Y, Clarke R et al. (2022). Gender differences in use of invasive diagnostic and therapeutic procedures for acute ischaemic heart disease in Chinese adults. nameOfConference DOI: 10.1136/heartjnl-2021-318988 QMRO: qmroHref Azhir A, Talebi S, Merino LH et al. (2022). BEHRTDAY: Dynamic Mortality Risk Prediction using Time-Variant COVID-19 Patient Specific Trajectories. nameOfConference DOI: doi QMRO: qmroHref Wu R, Williams C, Schlackow I et al. (2022). CALIBRATING CARDIOVASCULAR DISEASE POLICY MODEL USING LARGE COHORT DATA. nameOfConference DOI: doi QMRO: qmroHref Zhou J, Wu R, Williams C et al. (2022). EXCESS ANNUAL HOSPITAL COSTS DUE TO CARDIOVASCULAR EVENTS IN A CONTEMPORARY UK POPULATION TO INFORM HEALTH TECHNOLOGY ASSESSMENTS. nameOfConference DOI: doi QMRO: qmroHref Zhou J, Wu R, Williams C et al. (2022). P55 Excess Annual Hospital Costs Due to Cardiovascular Events in a Contemporary UK Population to Inform Health Technology Assessments. nameOfConference DOI: 10.1016/j.jval.2021.11.053 QMRO: qmroHref Wu R, Williams C, Schlackow I et al. (2022). P70 Calibrating Cardiovascular Disease Policy Model Using Large Cohort Data. nameOfConference DOI: 10.1016/j.jval.2021.11.068 QMRO: qmroHref Azhir A, Talebi S, Merino LH et al. (2022). Using Shapes of COVID-19 Positive Patient-Specific Trajectories for Mortality Prediction. nameOfConference DOI: doi QMRO: qmroHref Wu R, Rison S, Raisi-Estabragh Z et al. (2021). Gaps in antihypertensive and statin treatments and benefits of optimisation: a modelling study in a 1 million ethnically diverse urban population in UK. nameOfConference DOI: 10.1136/bmjopen-2021-052884 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/75858 Norton C, Syred J, Kerry S et al. (2021). Supported online self-management versus care as usual for symptoms of fatigue, pain and urgency/incontinence in adults with inflammatory bowel disease (IBD-BOOST): study protocol for a randomised controlled trial. nameOfConference DOI: 10.1186/s13063-021-05466-4 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/73549 Wu R, Williams C, Schlackow I et al. (2021). A model of lifetime health outcomes in cardiovascular disease based on clinical trials and large cohorts. nameOfConference DOI: 10.1093/eurheartj/ehab724.3149 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/74954 Wu R, Rison S, Raisi-Estabragh Z et al. (2021). Benefits from optimised antihypertensive and statin treatment in high risk people. European Society of Cardiology Congress 2021 DOI: doi QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/75860 Wu R, Rison S, Raisi-Estabragh Z et al. (2021). Benefits from optimised antihypertensive and statin treatment in high risk people. nameOfConference DOI: 10.1093/eurheartj/ehab724.2728 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/74955 Lui NMJ, Williams C, Keng MJ et al. (2021). Impact of adverse events on quality of life and hospital costs in secondary cardiovascular disease prevention. nameOfConference DOI: 10.1093/eurheartj/ehab724.3159 QMRO: qmroHref Leal J, Alva M, Gregory V et al. (2021). Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90). nameOfConference DOI: 10.1111/dme.14656 QMRO: qmroHref Halliday A, Bulbulia R, Bonati LH et al. (2021). Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy. nameOfConference DOI: 10.1016/S0140-6736(21)01910-3 QMRO: qmroHref Perera R, Stevens R, Aronson JK et al. (2021). Long-term monitoring in primary care for chronic kidney disease and chronic heart failure: a multi-method research programme. nameOfConference DOI: 10.3310/pgfar09100 QMRO: qmroHref Norton C, Syred J, Kerry S et al. (2021). Supported Online Self-Management Versus Care as Usual for Symptoms of Fatigue, Pain and Urgency/incontinence in Adults With Inflammatory Bowel Disease (IBD-BOOST): Study Protocol for a Randomized Controlled Trial.. nameOfConference DOI: 10.21203/rs.3.rs-62886/v1 QMRO: qmroHref Thorn JC, Davies CF, Brookes ST et al. (2021). Content of Health Economics Analysis Plans (HEAPs) for Trial-Based Economic Evaluations: Expert Delphi Consensus Survey. nameOfConference DOI: 10.1016/j.jval.2020.10.002 QMRO: qmroHref Alonso Fernandez S, Tan M, Wang C et al. (2021). Impact of the 2003-2018 population salt intake reduction programme in England: a modelling study. nameOfConference DOI: 10.1161/HYPERTENSIONAHA.120.16649 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/72199 Colligan G, Tsocheva I, Scales J et al. (2021). Investigating the impact of London’s Ultra Low Emission Zone on children’s health: Children’s Health in London and Luton (CHILL): Protocol for a prospective parallel cohort study. nameOfConference DOI: 10.1101/2021.02.04.21251049 QMRO: qmroHref Shlipak MG, Tummalapalli SL, Boulware LE et al. (2021). The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. nameOfConference DOI: 10.1016/j.kint.2020.10.012 QMRO: qmroHref Schlackow I, Simons C, Oke J et al. (2020). Long-term health outcomes of people with reduced kidney function in the UK: A modelling study using population health data. nameOfConference DOI: 10.1371/journal.pmed.1003478 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/69498 Lieberman D, Mangat H, Allen-Philbey K et al. (2020). Cladribine to halt deterioration in people with advanced multiple sclerosis (CHARIOTMS). nameOfConference DOI: doi QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/72152 Thalmann I, Preiss D, Schlackow I et al. (2020). Determinants of statin initiation and discontinuation in the secondary prevention of atherosclerotic cardiovascular disease in Scotland during 2009–2017. nameOfConference DOI: 10.1093/ehjci/ehaa946.3509 QMRO: qmroHref Tsiachristas A, West H, Oikonomou EK et al. (2020). Real world cost and health outcomes of patients presented with chest pain in England: which is the most cost-effective first-line test?. nameOfConference DOI: 10.1093/ehjci/ehaa946.3547 QMRO: qmroHref O'Halloran R, Mihaylova B, Cairns BJ et al. (2020). BMI and Cause-Specific Hospital Admissions and Costs: The UK Biobank Cohort Study.. nameOfConference DOI: 10.1002/oby.22812 QMRO: qmroHref Mach F, Baigent C, Catapano AL et al. (2020). 2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk. nameOfConference DOI: 10.15829/1560-4071-2020-3826 QMRO: qmroHref Levy M, Chen Y, Clarke R et al. (2020). Socioeconomic differences in health-care use and outcomes for stroke and ischaemic heart disease in China during 2009–16: a prospective cohort study of 0.5 million adults. nameOfConference DOI: 10.1016/S2214-109X(20)30078-4 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/69170 Mach F, Baigent C, Catapano AL et al. (2020). Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014)). nameOfConference DOI: 10.1016/j.atherosclerosis.2019.12.004 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/67763 Mach F, Baigent C, Catapano AL et al. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. nameOfConference DOI: 10.1093/eurheartj/ehz455 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/62584 Mach F, Baigent C, Catapano AL et al. (2020). Ghidul societăţii europene de cardiologie (Esc)/ societăţii europene de ateroscleroză (eas) pentru diagnosticul şi tratamentul dislipidemiilor 2019: modificările lipidice în vederea reducerii riscului cardiovascular. nameOfConference DOI: doi QMRO: qmroHref Authors/Task Force Members, ESC National Cardiac Societies, ESC Committee for Practice Guidelines (CPG) (2020). Erratum to "2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205].. nameOfConference DOI: 10.1016/j.atherosclerosis.2019.11.020 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/68917 Roukas C, Tomini F, Mihaylova B (2019). P49 UK cost-effectiveness value pyramid of asthma interventions. Driving quality improvement through education and training DOI: 10.1136/thorax-2019-btsabstracts2019.192 QMRO: qmroHref Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies (2019). 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.. nameOfConference DOI: 10.1016/j.atherosclerosis.2019.08.014 QMRO: qmroHref Keng MJ, Tsiachristas A, Leal J et al. (2019). Impact of achieving primary care targets in type 2 diabetes on health outcomes and healthcare costs. nameOfConference DOI: 10.1111/dom.13821 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/58831 Levy M, Chen Y, Clarke R et al. (2019). Declining socioeconomic inequalities in hospital care use and case fatality rates for stroke and ischaemic heart disease in China during 2009–16: a prospective study of 0·5 million adults. nameOfConference DOI: 10.1016/s0140-6736(19)32345-1 QMRO: qmroHref Thorn J, Davies CF, Brookes ST et al. (2019). Essential items for a Health Economics Analysis Plan (HEAP): expert Delphi consensus survey. nameOfConference DOI: doi QMRO: qmroHref Hopewell JC, Ibrahim M, Hill M et al. (2019). Impact of ADCY9 genotype on response to anacetrapib. nameOfConference DOI: 10.1161/CIRCULATIONAHA.119.041546 QMRO: qmroHref Oke JL, Feakins BG, Schlackow I et al. (publicationYear). Statistical models for the deterioration of kidney function in a primary care population: A retrospective database analysis. nameOfConference DOI: 10.12688/f1000research.20229.1 QMRO: qmroHref Schlackow I, Kent S, Herrington W et al. (2019). Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.. nameOfConference DOI: 10.1016/j.kint.2019.01.028 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/58061 Schlackow I, Kent S, Herrington W et al. (publicationYear). Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. nameOfConference DOI: 10.1016/j.kint.2019.01.028 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/58877 Edwards MR, Forbes G, MacDonald N et al. (2019). Optimisation of Perioperative Cardiovascular Management to Improve Surgical Outcome II (OPTIMISE II) trial: study protocol for a multicentre international trial of cardiac output-guided fluid therapy with low-dose inotrope infusion compared with usual care in patients undergoing major elective gastrointestinal surgery.. nameOfConference DOI: 10.1136/bmjopen-2018-023455 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/56225 Keng MJ, Tsiachristas A, Leal J et al. (2019). Impact of variation in Type 2 diabetes care on health outcomes and healthcare costs. nameOfConference DOI: doi QMRO: qmroHref Kent S, Aveyard P, Astbury N et al. (2019). Is Doctor Referral to a Low-Energy Total Diet Replacement Program Cost-Effective for the Routine Treatment of Obesity?. nameOfConference DOI: 10.1002/oby.22407 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/56074 MIHAYLOVA BA (2019). Efficacy and safety of statin therapy in older people: meta-analysis of individual participant data from 28 randomised controlled trials. nameOfConference DOI: 10.1016/S0140-6736(18)31942-1 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/55109 Oke JL, Feakins BG, Schlackow I et al. (2019). Statistical models for the deterioration of kidney function in a primary care population: A retrospective database analysis.. nameOfConference DOI: 10.12688/f1000research.20229.2 QMRO: qmroHref Kent S, Jebb S, Gray A et al. (2018). Body Mass Index and use and costs of primary care services among women aged 55 to 79 years in England: a cohort and linked data study. nameOfConference DOI: 10.1038/s41366-018-0288-6 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/53466 Castellani J, Mihaylova B, Siribié M et al. (2018). Household costs and time to treatment for children with severe febrile illness in rural Burkina Faso: The role of rectal artesunate. nameOfConference DOI: 10.1186/s12936-018-2526-8 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/49863 Herrington WG, Donovan K, Mihaylova B (2018). Authors’ reply. nameOfConference DOI: 10.1681/ASN.2018060612 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/58060 Mihaylova B, Collaborative HT-R (2018). Assessing cardiovascular risk in people with atherosclerotic vascular disease on intensive statin therapy. nameOfConference DOI: doi QMRO: qmroHref Mihaylova B (2018). P5083Assessing cardiovascular risk in people with atherosclerotic vascular disease on intensive statin therapy. nameOfConference DOI: 10.1093/eurheartj/ehy566.p5083 QMRO: qmroHref Jepson M, Elliott D, Conefrey C et al. (2018). An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. nameOfConference DOI: 10.1016/j.jclinepi.2018.02.018 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/58064 Marthi A, Donovan K, Haynes R et al. (2018). Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. nameOfConference DOI: 10.1681/ASN.2017121334 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/49783 Lokuge K, de Waard DD, Halliday A et al. (2018). Meta-Analysis of the Procedural Risks of Carotid Endarterectomy and Carotid Artery Stenting Over Time. nameOfConference DOI: 10.1016/j.jvs.2018.04.008 QMRO: qmroHref Morton RL, Schlackow I, Gray A et al. (2018). Impact of CKD on Household Income. nameOfConference DOI: 10.1016/j.ekir.2017.12.008 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/50063 Lokuge K, de Waard DD, Halliday A et al. (2018). Meta-analysis of the procedural risks of carotid endarterectomy and carotid artery stenting over time. nameOfConference DOI: 10.1002/bjs.10717 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/40323 Schlackow I, Kent S, Herrington W et al. (2017). A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. nameOfConference DOI: 10.1136/heartjnl-2016-310970 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/49503 Bowman L, Hopewell JC, Chen F et al. (2017). Effects of anacetrapib in patients with atherosclerotic vascular disease. nameOfConference DOI: 10.1056/NEJMoa1706444 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/58065 Kent S, Fusco F, Gray A et al. (2017). Body mass index and healthcare costs: a systematic literature review of individual participant data studies. nameOfConference DOI: 10.1111/obr.12560 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/49483 Clayton GL, Smith IL, Higgins JPT et al. (2017). The INVEST project: Investigating the use of evidence synthesis in the design and analysis of clinical trials. nameOfConference DOI: 10.1186/s13063-017-1955-y QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/42303 Schlackow I, Mihaylova B, Grp SHARPC (2017). A lifetime disease model based on an RCT: development, validation and applications. nameOfConference DOI: doi QMRO: qmroHref Thorn J, Ridyard C, Hughes D et al. (2017). Health economics analysis plans: the current state of play. nameOfConference DOI: doi QMRO: qmroHref Schlackow I, Gray A, Sharples L et al. (2017). Methods for extrapolation from clinical trial data to inform economic evaluations: a taxonomy. nameOfConference DOI: doi QMRO: qmroHref de Waard DD, Halliday A, de Borst GJ et al. (2017). Choices of Stent and Cerebral Protection in the Ongoing ACST-2 Trial: A Descriptive Study.. nameOfConference DOI: 10.1016/j.ejvs.2016.12.034 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/58058 Kent S, Green J, Reeves G et al. (2017). Hospital costs in relation to body-mass index in 1·1 million women in England: a prospective cohort study. nameOfConference DOI: 10.1016/S2468-2667(17)30062-2 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/49626 Bowman L, Chen F, Sammons E et al. (2017). Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. nameOfConference DOI: 10.1016/j.ahj.2017.02.021 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/58063 Achelrod D, Gray A, Preiss D et al. (2017). Cholesterol- and blood-pressure-lowering drug use for secondary cardiovascular prevention in 2004-2013 Europe. nameOfConference DOI: 10.1177/2047487316676906 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/50384 Herrington WG, Emberson J, Mihaylova B et al. (2016). Are statins useful in patients with advanced chronic kidney disease? – Authors' reply. nameOfConference DOI: 10.1016/S2213-8587(16)30266-2 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/50943 Thorn J, Ridyard C, Hughes D et al. (2016). PRM221 Health Economics Analysis Plans: Where Are We Now?. nameOfConference DOI: 10.1016/j.jval.2016.09.291 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/58062 Lokuge K, de Waard D, Bulbulia R et al. (2016). Procedural risks of carotid endarterectomy and carotid artery stenting have improved since 2005: Results from a systematic review of observational studies. nameOfConference DOI: doi QMRO: qmroHref Herrington WG, Emberson J, Mihaylova B et al. (2016). Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. nameOfConference DOI: 10.1016/S2213-8587(16)30156-5 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/50603 Kent S, Haynes R, Hopewell JC et al. (2016). Effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs. nameOfConference DOI: 10.1161/CIRCOUTCOMES.115.002592 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/51205 Reith C, Blackwell L, Emberson J et al. (2016). Protocol for analyses of adverse event data from randomized controlled trials of statin therapy. nameOfConference DOI: 10.1016/j.ahj.2016.01.016 QMRO: qmroHref Mihaylova B, Schlackow I, Herrington W et al. (2016). Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: Results of the study of heart and renal protection (SHARP). nameOfConference DOI: 10.1053/j.ajkd.2015.09.020 QMRO: qmroHref Morton RL, Schlackow I, Staplin N et al. (2016). Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. nameOfConference DOI: 10.1053/j.ajkd.2015.07.021 QMRO: qmroHref Castellani J, Nsungwa-Sabiiti J, Mihaylova B et al. (2016). Impact of improving community-based access to malaria diagnosis and treatment on household costs. nameOfConference DOI: 10.1093/cid/ciw623 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/39443 Castellani J, Mihaylova B, Ajayi IO et al. (2016). Quantifying and valuing community healthworker time in improving access to malaria diagnosis and treatment. nameOfConference DOI: 10.1093/cid/ciw629 QMRO: https://qmro.qmul.ac.uk/xmlui/handle/123456789/50543 Morton RL, Schlackow I, Mihaylova B et al. (2016). The impact of social disadvantage in moderate-to-severe chronic kidney disease: An equity-focused systematic review. nameOfConference DOI: 10.1093/ndt/gfu394 QMRO: qmroHref Lokuge K, Halliday A, Bulbulia R et al. (2015). Systematic review of randomised and observational evidence of effects of treatments of carotid stenosis to prevent stroke. nameOfConference DOI: 10.1186/1745-6215-16-s2-p164 QMRO: qmroHref Morton RL, Schlackow I, Staplin N et al. (2015). FP329IMPACT OF EDUCATIONAL ATTAINMENT ON HEALTH OUTCOMES IN MODERATE-TO-SEVERE CHRONIC KIDNEY DISEASE. nameOfConference DOI: 10.1093/ndt/gfv175.11 QMRO: qmroHref Kent S, Schlackow I, Lozano-Kühne J et al. (2015). What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?. nameOfConference DOI: 10.1186/s12882-015-0054-0 QMRO: qmroHref Castellani J, Mihaylova B, Evers SMAA et al. (2015). Out-of-pocket costs and other determinants of access to healthcare for children with febrile illnesses: A case-control study in rural Tanzania. nameOfConference DOI: 10.1371/journal.pone.0122386 QMRO: qmroHref Alva ML, Gray A, Mihaylova B et al. (2015). The impact of diabetes-related complications on healthcare costs: New results from the UKPDS (UKPDS 84). nameOfConference DOI: 10.1111/dme.12647 QMRO: qmroHref PLOS ONE Staff (2015). Correction: Out-of-Pocket Costs and Other Determinants of Access to Healthcare for Children with Febrile Illnesses: A Case-Control Study in Rural Tanzania.. nameOfConference DOI: 10.1371/journal.pone.0128166 QMRO: qmroHref Fulcher J, O'Connell R, Voysey M et al. (2015). Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174 000 participants in 27 randomised trials. nameOfConference DOI: 10.1016/S0140-6736(14)61368-4 QMRO: qmroHref Lokuge K, Halliday A, Bulbulia R et al. (2015). Systematic review of randomised and observational evidence of effects of treatments of carotid stenosis to prevent stroke. nameOfConference DOI: doi QMRO: qmroHref Alva M, Gray A, Mihaylova B et al. (2014). The effect of diabetes complications on health-related quality of life: The importance of longitudinal data to address patient heterogeneity. nameOfConference DOI: 10.1002/hec.2930 QMRO: qmroHref Schlackow I, Mihaylova B (2013). Developing a lifetime disease model from RCT data using parametric models with time-updated covariates. nameOfConference DOI: 10.1186/1745-6215-14-s1-o24 QMRO: qmroHref Halliday A, Bulbulia R, Gray W et al. (2013). Status update and interim results from the asymptomatic carotid surgery trial-2 (ACST-2). nameOfConference DOI: 10.1016/j.ejvs.2013.07.020 QMRO: qmroHref Mihaylova B, Emberson J, Blackwell L et al. (2012). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. nameOfConference DOI: 10.1016/S0140-6736(12)60367-5 QMRO: qmroHref Mihaylova B, Emberson J, Keech A et al. (2012). Authors' reply. nameOfConference DOI: 10.1016/S0140-6736(12)62027-3 QMRO: qmroHref Heart Protection Study Collaborative Group (2011). Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.. nameOfConference DOI: 10.1016/S0140-6736(11)61125-2 QMRO: qmroHref Mihaylova B, Briggs A, O'Hagan A et al. (2011). Review of statistical methods for analysing healthcare resources and costs. nameOfConference DOI: 10.1002/hec.1653 QMRO: qmroHref Alva M, Gray AM, Mihaylova B et al. (2011). Outpatient Resource Utilization of Type-2 Diabetes Patients: New Evidence from the UKPDS. nameOfConference DOI: doi QMRO: qmroHref Alva ML, Gray A, Mihaylova B et al. (2011). The effect of diabetes complications on health-related quality of life: estimating the bias due to unobserved heterogeneity using the UKPDS. nameOfConference DOI: 10.1186/1745-6215-12-s1-a64 QMRO: qmroHref Buchanan J, Mihaylova B, Gray A et al. (2010). Cost-effectiveness of pre-referral antimalarial, antibacterial, and combined rectal formulations for severe febrile illness. nameOfConference DOI: 10.1371/journal.pone.0014446 QMRO: qmroHref Maude RJ, Mihaylova B, Warsame M et al. (2010). RECTAL AND INTRAVENOUS ARTESUNATE FOR SEVERE MALARIA: MODELLING THE IMPACT OF ARTEMISININ RESISTANCE. nameOfConference DOI: doi QMRO: qmroHref Alva ML, Gray A, Mihaylova B et al. (2010). Estimating the quality of life impact of diabetes related complications: new results from the UKPDS. nameOfConference DOI: doi QMRO: qmroHref Mihaylova B, Pitman R, Tincello D et al. (2010). Cost-effectiveness of duloxetine: The stress urinary incontinence treatment (SUIT) study. nameOfConference DOI: 10.1111/j.1524-4733.2010.00729.x QMRO: qmroHref Mihaylova B, Briggs A, Hlatky M et al. (2009). Statin cost-effectiveness in the United States for people at different vascular risk levels. nameOfConference DOI: 10.1161/CIRCOUTCOMES.108.808469 QMRO: qmroHref Briggs A, Mihaylova B, Sculpher M et al. (2007). Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. nameOfConference DOI: 10.1136/hrt.2005.086728 QMRO: qmroHref Mihaylova B, Briggs A, Armitage J et al. (2006). Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from randomised trial of 20 536 people. nameOfConference DOI: 10.1136/bmj.38993.731725.BE QMRO: qmroHref Briggs A, Mihaylova B, Sculpher M et al. (2006). The cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. nameOfConference DOI: doi QMRO: qmroHref Briggs A, Mihaylova B, Sculpher M et al. (2006). The cost-effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. nameOfConference DOI: doi QMRO: qmroHref Mihaylova B, Armitage J, Briggs A et al. (2005). Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial. nameOfConference DOI: doi QMRO: qmroHref Mihaylova B, Briggs A, Armitage J et al. (2005). Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: Economic analysis of a randomised trial in 20 536 individuals. nameOfConference DOI: 10.1016/S0140-6736(05)63014-0 QMRO: qmroHref Briggs A, Armitage J, Gray A et al. (2003). Economic evaluation of the Heart Protection Study. nameOfConference DOI: doi QMRO: qmroHref Collins R, Armitage J, Parish S et al. (2003). MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.. nameOfConference DOI: 10.1016/s0140-6736(03)13636-7 QMRO: qmroHref Heart Protection Study Collaborative Group (2002). MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial.. nameOfConference DOI: 10.1016/S0140-6736(02)09328-5 QMRO: qmroHref Heart Protection Study Collaborative Group (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.. nameOfConference DOI: 10.1016/S0140-6736(02)09327-3 QMRO: qmroHref Bryant J, Loveman E, Chase D et al. (2002). Clinical effectiveness and cost-effectiveness of growth hormone in adults in relation to impact on quality of life: A systematic review and economic evaluation. nameOfConference DOI: 10.3310/hta6190 QMRO: qmroHref Bryant J, Cave C, Mihaylova B et al. (2002). Clinical effectiveness and cost-effectiveness of growth hormone in children: A systematic review and economic evaluation. nameOfConference DOI: 10.3310/hta6180 QMRO: qmroHref Supervision Chris Roukas, Bowel Research UK, “Resource use, quality of life and value of self-management of IBD” Anya Jacobs, Wellcome Trust PhD Programme in Science Health data in practice: human-centred science, “Developing a health economic framework for assessing asthma management strategies in UK primary care”